icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
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
Qb2hTFz0kBfTMdta
Listen
